Alpha 2.0
Login Register
» Authors » Nicolas Salvadori

Nicolas Salvadori

Explore the profile of Nicolas Salvadori including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 233
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Pharmacology
Top 10 Co-Authors
Gonzague Jourdain
Nicole Ngo-Giang-Huong
Tim R Cressey
Woottichai Khamduang
Jullapong Achalapong
Marc Lallemant
Luc Decker
Wasna Sirirungsi
Jean Yves Mary
Chureeratana Bowonwatanuwong
Published In
J Acquir Immune Defic Syndr
Clin Infect Dis
PLoS One
J Int AIDS Soc
Viruses
Affiliations
Soon will be listed here.
Recent Articles
1.
Single Doses of Pediatric Dolutegravir-Dispersible Tablets in Neonates Support Multi-Dosing: PETITE-DTG Study
Cressey T, Salvadori N, Rabie H, du Toit S, Than-In-At K, Groenewald M, et al.
J Acquir Immune Defic Syndr . 2025 Feb; PMID: 39972540
Background: Dolutegravir dispersible tablets (DTG-DT) are approved for infants ≥4 weeks and ≥3 kg but their suitability for neonates remains unknown. Methods: PETITE-DTG is a Phase I/II, open-label, single center,...
2.
Real-world evidence of survival benefit of remdesivir: study of 419 propensity score-matched patients hospitalized over the alpha and delta waves of COVID-19 in New Orleans, LA
Salvadori N, Fridman M, Chiang M, Chen L, Wang C, Lee E, et al.
Front Med (Lausanne) . 2024 May; 11:1390164. PMID: 38818394
Background: The direct acting antiviral remdesivir (RDV) has shown promising results in randomized clinical trials. This study is a unique report of real clinical practice RDV administration for COVID-19 from...
3.
Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment
Panjasawatwong N, Avihingsanon A, Menetrey C, Ribeiro I, Salvadori N, Swanson A, et al.
Antimicrob Agents Chemother . 2024 May; 68(7):e0000824. PMID: 38767383
Ravidasvir (RDV) is a novel NS5A inhibitor that exhibits potent pan-genotypic inhibition of hepatitis C virus (HCV) replication. Sofosbuvir (SOF) plus RDV was demonstrated to be efficacious and safe in...
4.
Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand
Salvadori N, Jourdain G, Krittayaphong R, Siripongboonsitti T, Kongsaengdao S, Atipornwanich K, et al.
Int J Infect Dis . 2024 Apr; 143:107021. PMID: 38561040
Objectives: Evaluate and compare the efficacy and safety of molnupiravir and favipiravir in outpatients with mild to moderate COVID-19 and at risk of severe COVID-19. Methods: In an open-label, parallel-group,...
5.
Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial
Bekker A, Salvadori N, Rabie H, du Toit S, Than-In-At K, Groenewald M, et al.
Lancet HIV . 2024 Jan; 11(2):e86-e95. PMID: 38296364
Background: Existing solid antiretroviral fixed-dose combination formulations are preferred over liquid formulations in children, but their suitability for neonates is unknown. We evaluated the pharmacokinetics and safety of paediatric abacavir-lamivudine...
6.
Hepatitis B prevalence and associated factors in adults presenting for infection screening in northern Thailand
Salvadori N, Gauthier L, Guy M, Ngo-Giang-Huong N, Khamduang W, Decker L, et al.
J Virus Erad . 2024 Jan; 9(4):100356. PMID: 38161321
Background And Aims: Hepatitis B is a leading cause of morbidity and mortality worldwide. In view of the World Health Organization 2030 targets, effective screening of chronic infection is crucial....
7.
Uptake, acceptability and interpretability of 3-in-1 rapid blood self-testing for HIV, hepatitis B and hepatitis C
Salvadori N, Achalapong J, Boontan C, Piriya C, Arunothong S, Nangola S, et al.
J Int AIDS Soc . 2022 Dec; 25(12):e26053. PMID: 36562652
Introduction: Early diagnosis is key to achieving the goal of eliminating transmission of HIV and hepatitis B and C. We assessed the uptake, acceptability and interpretability of self-testing using a...
8.
Chronic Kidney Disease in a Large National Human Immunodeficiency Virus Treatment Program
Paengsai N, Noppakun K, Jourdain G, Cressey T, Salvadori N, Chaiwarith R, et al.
Healthcare (Basel) . 2022 Aug; 10(8). PMID: 36011147
Tenofovir disoproxil fumarate (TDF) is associated with a risk of chronic kidney disease (CKD), especially in Asian populations. Data from the Thai national health insurance system was used to assess...
9.
Zika Virus Immunoglobulin G Seroprevalence among Young Adults Living with HIV or without HIV in Thailand from 1997 to 2017
Choyrum S, Wangsaeng N, Nechba A, Salvadori N, Saisom R, Achalapong J, et al.
Viruses . 2022 Feb; 14(2). PMID: 35215960
Zika virus (ZIKV) epidemiological data in Thailand are limited. We assessed ZIKV IgG seroprevalence among young adults during 1997-2017 and determined factors associated with ZIKV IgG seropositivity. This retrospective laboratory...
10.
Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus
Liegeon G, Ngo-Giang-Huong N, Salvadori N, Bunpo P, Cressey R, Achalapong J, et al.
J Antimicrob Chemother . 2022 Jan; 77(4):1111-1118. PMID: 35045168
Background: Data evaluating the risk of proximal tubular dysfunction in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission (PMTCT) of HBV are scarce. Objectives: To assess the...